Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: A retrospective assessment

British Journal of Cancer

Volumn 109, Issue 10, 2013, Pages 2523-2532

  Thiel, U ^a   Koscielniak, E ^b   Blaeschke, F ^a   Grunewald, T G P ^a   Badoglio, M ^c   Diaz, M A ^d   Paillard, C ^e   Prete, A ^f   Ussowicz, M ^g   Lang, P ^h   Fagioli, F ⁱ   Lutz, P ^j   Ehninger, G ^k   Schneider, P ^l   Santucci, A ^m   Bader, P ⁿ   Gruhn, B ^o   Faraci, M ^p   Antunovic, P ^q   Styczynski, J ^r   Kruger W H ^s   Castagna, L ^t   Rohrlich, P ^u   Ouachee Chardin M ^v   Salmon, A ^w   Peters, C ^x   Bregni, M ^y   Burdach, S ^a   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b OLGAHOSPITAL   (Germany)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^j HÔPITAL DE HAUTEPIERRE   (France)

^k UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^l ROUEN UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY OF PERUGIA   (Italy)

ⁿ GOETHE UNIVERSITY   (Germany)

^o JENA UNIVERSITY HOSPITAL   (Germany)

^p G GASLINI INSTITUTE   (Italy)

^q LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^r NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^s UNIVERSITY OF GREIFSWALD   (Germany)

^t HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^u UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^v HÔPITAL ROBERT DEBRÉ   (France)

^w CHU NANCY BRABOIS   (France)

^x ST ANNA CHILDREN S HOSPITAL   (Austria)

^y OSPEDALE DI CIRCOLO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TOPOTECAN; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REGIMEN; DRUG MEGADOSE; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN TISSUE; INFECTION; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; RISK FACTOR; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84887838962     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.630     Document Type: Article

References (49)

1. Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, Humphrey JL, Rager A, Richards K, Wayne AS, Mackall CL (2012) Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant 18(5): 698-707.
2. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S, Gress R (2004) Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 22(19): 3886-3892.
3. Bregni M, Bernardi M, Ciceri F, Peccatori J (2004) Allogeneic stem cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol 26(1-2): 95-108.
4. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Korholz D, Pape H, Dunst J, Kahn T, Willers R, Engel B, Dirksen U, Kramm C, Nurnberger W, Heyll A, Ladenstein R, Gadner H, Jurgens H, Go el U (2000) Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 11(11): 1451-1462.
5. Carli M, Colombatti R, Oberlin O, Bisogno G, Treuner J, Koscielniak E, Tridello G, Garaventa A, Pinkerton R, Stevens M (2004) European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 22(23): 4787-4794.
6. Carli M, Colombatti R, Oberlin O, Stevens M, Masiero L, Frascella E, Koscielniak E, Treuner J, Pinkerton CR (1999) High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 17(9): 2796-2803.
7. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343(11): 750-758.
8. Chisholm JC, Marandet J, Rey A, Scopinaro M, de Toledo JS, Merks JH, O'Meara A, Stevens MC, Oberlin O (2011) Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 29(10): 1319-1325.
9. Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM (2012) FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma. Clin Cancer Res 18(14): 3780-3790.
10. Dalerba P, Frascella E, Macino B, Mandruzzato S, Zambon A, Rosolen A, Carli M, Ninfo V, Zanovello P (2001) MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas. Int J Cancer 93(1): 85-90.
11. Dantonello TM, Int-Veen C, Harms D, Leuschner I, Schmidt BF, Herbst M, Juergens H, Scheel-Walter HG, Bielack SS, Klingebiel T, Dickerhoff R, Kirsch S, Brecht I, Schmelzle R, Greulich M, Gadner H, Greiner J, Marky I, Treuner J, Koscielniak E (2009) Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol 27(9): 1446-1455.
12. Donker AE, Hoogerbrugge PM, Mavinkurve-Groothuis AM, van de Kar NC, Boetes C, Hulsbergen-van de Kaa CA, Groot-Loonen JJ (2009) Metastatic rhabdomyosarcoma cured after chemotherapy and allogeneic SCT. Bone Marrow Transplant 43(2): 179-180.
13. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32): 5233-5239.
14. Fulda S (2012) Cell death pathways as therapeutic targets in rhabdomyosarcoma. Sarcoma 2012: 326210.
15. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202(7): 907-912.
16. Grunewald TG, Greulich N, Kontny U, Fruhwald M, Rutkowski S, Kordes U, Scheurlen W, Schmidt W, Stachel D, Metzler M, Mittler U, Graf N, Benesch M, Burdach S (2012) Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klin Padiatr 224(3): 124-131.
17. Jolesch A, Elmer K, Bendz H, Issels RD, Noessner E (2012) Hsp70, a messenger from hyperthermia for the immune system. Eur J Cell Biol 91(1): 48-52.
18. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103(3): 767-776.
19. Koscielniak E, Gross-Wieltsch U, Treuner J, Winkler P, Klingebiel T, Lang P, Bader P, Niethammer D, Handgretinger R (2005) Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol 23(1): 242-244.
20. Koscielniak E, Klingebiel TH, Peters C, Hermann J, Burdach ST, Bender-Gotze C, Muller-Weihrich ST, Treuner J (1997) Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 19(3): 227-231.
21. Kuci S, Rettinger E, Voss B, Weber G, Stais M, Kreyenberg H, Willasch A, Kuci Z, Koscielniak E, Kloss S, von Laer D, Klingebiel T, Bader P (2010) Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 95(9): 1579-1586.
22. Lang P, Pfeiffer M, Muller I, Schumm M, Ebinger M, Koscielniak E, Feuchtinger T, Foll J, Martin D, Handgretinger R (2006) Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr 218(6): 321-326.
23. Lundqvist A, Childs R (2005) Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J Immunother 28(4): 281-288.
24. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R (2006) Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24(31): 5060-5069.
25. Mapara MY, Sykes M (2004) Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22(6): 1136-1151.
26. Marcus A, Waks T, Eshhar Z (2011) Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood 118(4): 975-983.
27. Misawa A, Hosoi H, Tsuchiya K, Iehara T, Sawada T, Sugimoto T (2003) Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation. Pediatr Hematol Oncol 20(2): 151-155.
28. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796): 126-129.
29. Ohta H, Hashii Y, Yoshida H, Kusuki S, Tokimasa S, Yoneda A, Fukuzawa M, Inoue N, Hara J, Kusafuka T, Ozono K (2011) Allogeneic hematopoietic stem cell transplantation against recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 33(1): e35-e38.
30. Pappo AS, Shapiro DN, Crist WM, Maurer HM (1995) Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 13(8): 2123-2139.
31. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ (2012) Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18): 4133-4141.
32. Peinemann F, Kroger N, Bartel C, Grouven U, Pittler M, Erttmann R, Kulig M (2011) High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma-a systematic review. PLoS One 6(2): e17127.
33. Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, Sola JE (2011) Rhabdomyosarcoma in children: a SEER population based study. J Surg Res 170(2): e243-e251.
34. Perez-Martinez A, Leung W, Munoz E, Iyengar R, Ramirez M, Vicario JL, Lassaletta A, Sevilla J, Gonzalez-Vicent M, Madero L, Diaz-Perez MA (2009) KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer 53(1): 120-124.
35. Reisner Y, Hagin D, Martelli MF (2011) Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 118(23): 6006-6017.
36. Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers ME, Friedman DL, Horowitz MM, Wingard JR, Deeg HJ (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113(5): 1175-1183.
37. Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4): 381-387.
38. Spranger S, Jeremias I, Wilde S, Leisegang M, Starck L, Mosetter B, Uckert W, Heemskerk MH, Schendel DJ, Frankenberger B (2012) TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. Blood 119(15): 3440-3449.
39. Stevens MC (2005) Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol 6(2): 77-84.
40. Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23(12): 2618-2628.
41. Thiel U, Pirson S, Muller-Spahn C, Conrad H, Busch DH, Bernhard H, Burdach S, Richter GH (2011a) Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells. Br J Cancer 104(6): 948-956.
42. Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T, Basu O, Borkhardt A, Laws HJ, Kodera Y, Yoshimi A, Peters C, Ladenstein R, Pession A, Prete A, Urban EC, Schwinger W, Bordigoni P, Salmon A, Diaz MA, Afanasyev B, Lisukov I, Morozova E, Toren A, Bielorai B, Korsakas J, Fagioli F, Caselli D, Ehninger G, Gruhn B, Dirksen U, Abdel-Rahman F, Aglietta M, Mastrodicasa E, Torrent M, Corradini P, Demeocq F, Dini G, Dreger P, Eyrich M, Gozdzik J, Guilhot F, Holler E, Koscielniak E, Messina C, Nachbaur D, Sabbatini R, Oldani E, Ottinger H, Ozsahin H, Schots R, Siena S, Stein J, Sufliarska S, Unal A, Ussowicz M, Schneider P, Woessmann W, Jurgens H, Bregni M, Burdach S (2011b) No improvement of survival with reduced-versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol 22(7): 1614-1621.
43. Tomblyn M, Lazarus HM (2008) Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant 42(9): 569-579.
44. Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V, Banchereau J, Palucka K (2010) Harnessing human dendritic cell subsets for medicine. Immunol Rev 234(1): 199-212.
45. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE (2003) Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10): 3829-3836.
46. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ (2006) CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 8(5): 394-401.
47. Weber J (2010) Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 37(5): 430-439.
48. Wernicke CM, Grunewald TG, Juenger H, Kuci S, Kuci Z, Koehl U, Mueller I, Doering M, Peters C, Lawitschka A, Kolb HJ, Bader P, Burdach S, von Luettichau I (2011) Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases. Int Arch Med 4(1): 27.
49. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B (2010) Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 70(12): 4850-4858.